96 results
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
A Serious and Life-Threatening Disease pLGGs are chronic and For the majority of pLGG patients in the relapsed setting, there is no standard of care … 7,8 vast majority of patients still require systemic therapy their life trajectory over the Due to high rate of disease recurrence, most patients
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
12 Jun 24
Regulation FD Disclosure
8:07am
Type Of Brain Tumor In Children A Serious and Life-Threatening Disease pLGGs are chronic and For the majority of pLGG patients in the relapsed setting … in treatment, the morbidity that can impact 7,8 vast majority of patients still require systemic therapy their life trajectory over the Due to high rate
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
Type Of Brain Tumor In Children A Serious and Life-Threatening Disease pLGGs are chronic and For the majority of pLGG patients in the relapsed setting … , the morbidity that can impact 7,8 vast majority of patients still require systemic therapy their life trajectory over the Due to high rate
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
the long term1 A Serious and Life-Threatening Disease For the majority of pLGG patients in the relapsed setting, there is no standard of care … a significant role in treatment, the vast majority of patients still require systemic therapy7,8 Due to high rate of disease recurrence, most patients
8-K
d3m0ibb q9a06etuci
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
b40wcz0 8j9d
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
fiqzjhi 1dz
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
0nnht
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
eb67wj5i9ladwu
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
42gcg
8 Jan 24
Regulation FD Disclosure
8:30am
S-8
EX-99.1
bem8n1fd
4 Jan 24
Registration of securities for employees
4:06pm
8-K
EX-99.2
ai84nv
17 Nov 23
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
7:07am
8-K
EX-99.2
re3qdiiajpd1bw
6 Nov 23
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
9g9bx9oi8ngws9
30 Oct 23
Regulation FD Disclosure
8:12am
8-K
EX-99.2
2hu k7g37r7
30 Oct 23
Regulation FD Disclosure
8:12am